We are joined by Charles De Bock, at EHA 2019 to discuss his presentation on safe targeting of T-cell acute lymphoblastic leukaemia by subunit selective gamma-secretase inhibition.
Questions
1. What is the rationale for the use of gamma‐secretase inhibitors for patients with T-cell acute lymphoblastic leukaemia? (0:05)
2. What are the limitations of current gamma‐secretase inhibitors? (0:45)
3. Could you tell us a little about your study investigating subunit specific gamma-secretase inhibition? (1:38)
4. What will be the next steps in this research? (3:10)
Charles de Bock has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
